JPWO2021170838A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021170838A5 JPWO2021170838A5 JP2022551667A JP2022551667A JPWO2021170838A5 JP WO2021170838 A5 JPWO2021170838 A5 JP WO2021170838A5 JP 2022551667 A JP2022551667 A JP 2022551667A JP 2022551667 A JP2022551667 A JP 2022551667A JP WO2021170838 A5 JPWO2021170838 A5 JP WO2021170838A5
- Authority
- JP
- Japan
- Prior art keywords
- therapy
- shock
- dpp3
- state
- stratification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179567A JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159848 | 2020-02-27 | ||
| EP20159848.9 | 2020-02-27 | ||
| PCT/EP2021/054911 WO2021170838A1 (en) | 2020-02-27 | 2021-02-26 | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179567A Division JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516615A JP2023516615A (ja) | 2023-04-20 |
| JP2023516615A5 JP2023516615A5 (https=) | 2024-02-29 |
| JPWO2021170838A5 true JPWO2021170838A5 (https=) | 2024-02-29 |
Family
ID=69742802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551667A Pending JP2023516615A (ja) | 2020-02-27 | 2021-02-26 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
| JP2025179567A Pending JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179567A Pending JP2026035582A (ja) | 2020-02-27 | 2025-10-24 | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230193348A1 (https=) |
| EP (1) | EP4111204A1 (https=) |
| JP (2) | JP2023516615A (https=) |
| CN (1) | CN115244401A (https=) |
| AU (1) | AU2021228207A1 (https=) |
| BR (1) | BR112022015215A2 (https=) |
| CA (1) | CA3172349A1 (https=) |
| MX (1) | MX2022010672A (https=) |
| WO (1) | WO2021170838A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022010564A (es) * | 2020-02-27 | 2022-11-30 | Adrenomed Ag | Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque. |
| KR20250042158A (ko) | 2022-07-29 | 2025-03-26 | 아드레노메드 아게 | 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| CN119630969A (zh) | 2022-07-29 | 2025-03-14 | 4Teen4制药有限公司 | 预测患有败血症性休克的患者中的dpp3增加 |
| WO2025248139A1 (en) | 2024-05-31 | 2025-12-04 | 4TEEN4 Pharmaceuticals GmbH | Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| AU2010332932B2 (en) | 2009-12-14 | 2013-01-17 | Navigo Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RU2569745C2 (ru) | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| PL2594588T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| SG11201402362VA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| DK2780371T3 (en) | 2011-11-16 | 2019-02-25 | Adrenomed Ag | ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE |
| EP4086283A1 (en) | 2011-11-16 | 2022-11-09 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| AU2017252212B2 (en) * | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| SG11202002268XA (en) * | 2017-10-18 | 2020-04-29 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| MY202502A (en) * | 2017-10-25 | 2024-05-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
-
2021
- 2021-02-26 CN CN202180015815.5A patent/CN115244401A/zh active Pending
- 2021-02-26 US US17/802,799 patent/US20230193348A1/en active Pending
- 2021-02-26 CA CA3172349A patent/CA3172349A1/en active Pending
- 2021-02-26 MX MX2022010672A patent/MX2022010672A/es unknown
- 2021-02-26 EP EP21707707.2A patent/EP4111204A1/en active Pending
- 2021-02-26 BR BR112022015215A patent/BR112022015215A2/pt unknown
- 2021-02-26 WO PCT/EP2021/054911 patent/WO2021170838A1/en not_active Ceased
- 2021-02-26 AU AU2021228207A patent/AU2021228207A1/en active Pending
- 2021-02-26 JP JP2022551667A patent/JP2023516615A/ja active Pending
-
2025
- 2025-10-24 JP JP2025179567A patent/JP2026035582A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102886883B1 (ko) | Dpp3을 결정하는 방법 및 치료 방법 | |
| JP2025133108A5 (https=) | ||
| JP7654597B2 (ja) | 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン | |
| EP4021571B1 (en) | Therapy guidance and/or therapy monitoring for treatment of shock | |
| BR112020005682A2 (pt) | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) | |
| JP2026035582A (ja) | ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ | |
| US20230104578A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock | |
| CN115769076A (zh) | 感染冠状病毒的患者中的dpp3 | |
| JPWO2021170838A5 (https=) | ||
| EP4633659A1 (en) | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients | |
| JP2025527173A (ja) | 敗血性ショックを有する患者におけるｄｐｐ３の増加の予測 | |
| RU2838370C1 (ru) | Dpp3 для осуществления, мониторинга и стратификации терапии nt-adm антителами у пациентов с шоком | |
| WO2024200862A1 (en) | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline | |
| JP2026513177A (ja) | 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤 | |
| CN119604526A (zh) | 用于治疗或预防休克的抗肾上腺髓质素（ADM）抗体或抗ADM抗体片段或抗ADM非Ig支架 | |
| KR20220145898A (ko) | 쇼크 환자의 치료에 사용하기 위한 항-아드레노메둘린 (adm) 결합제 | |
| NZ747387A9 (en) | Methods for determining dpp3 and therapeutic methods | |
| NZ747387B2 (en) | Methods for determining dpp3 and therapeutic methods | |
| HK1226484B (zh) | 预测出现主要不良心脏事件的风险的方法 |